News

Seelos Therapeutics announced it is beginning, earlier than expected, a preclinical study into its investigational gene therapy candidate for Parkinson’s disease called SLS-004. The exact nature of this early research work was not detailed in a press release. Nerve cell damage in Parkinson’s is caused by the buildup of toxic forms…

The Michael J. Fox Foundation (MJFF) is offering a new online Parkinson’s disease educational series aimed at researchers and clinicians. Parkinson’s Disease Therapeutics Webinars, a free four-part series, starts June 16 and will feature presentations by leaders in Parkinson’s research and treatment development. “We know people with…

Scientists have created a special matrix that allowed them to differentiate stem cells into nerve cells that, when transplanted into a rat model of Parkinson’s disease, eased the animals’ symptoms by replacing those nerve cells lost to the disease. This matrix is also able to stimulate differentiation of stem…

Deep brain stimulation with Boston Scientific’s Vercise system led to sustained “on” periods without troublesome dyskinesia and improvements in both motor and non-motor symptoms of Parkinson’s disease for at least one year, updated findings from the INTREPID trial show. Use of the Vercise Deep Brain Stimulation system in…

A consensus statement from the Parkinson’s Foundation declares there isn’t enough data yet to draw reliable conclusions about whether medical cannabis products might be beneficial in treating Parkinson’s disease, and calls for more research. For people with Parkinson’s who choose to use such products, the statement urges caution,…

Chemicals in diesel exhaust can trigger the formation of toxic protein clumps and the death of nerve cells — hallmarks of Parkinson’s disease — by preventing the cell’s natural disposal mechanisms from working properly, a study in fish and human cells shows. The findings also demonstrated that boosting these cellular…

Infections with the new coronavirus may manifest in people with Parkinson’s as a rapid worsening of disease symptoms, hindering early and accurate diagnosis of infections in this population, according to a case report on two patients. It also points to a possibility of more severe infections in these patients, but…

The U.S. Food and Drug Administration has approved Sunovion’s Kynmobi (apomorphine hydrochloride) as an on-demand sublingual treatment for off episodes, or times when medication wears off, in people with Parkinson’s disease. The medication, formerly known as APL-130277, is an apomorphine film that is placed under-the-tongue (sublingual administration) when…